ADDITIVE EFFECTS OF ANTI-CD3 AND ANTI-CD28 ON PROLONGATION OF ALLOGENEIC SKINGRAFT SURVIVAL
Xue-Zhong Yu,Yoshio Nitta,Sasha J. Bidwell,Claudio Anasetti
DOI: https://doi.org/10.1097/00007890-200112150-00030
2001-01-01
Transplantation
Abstract:T cells play a critical role in allograft rejection. T-cell activation requires antigen recognition by the T-cell receptor (TCR)/CD3 complex and costimulation of accessory receptors. Non-FcR-binding anti-CD3ε antibodies (Abs) produce immunosuppression without the toxicity associated with Fc-dependent activation (1). Non-FcR-binding anti-CD3ε Abs may induce T-cell anergy, skew the T-cell repertoire toward the Th2 phenotype, modulate the TCR, and block antigen recognition (1). We have found that a critical mechanism of immunosuppression by non-FcR-binding anti-CD3ε Abs is the induction of apoptosis in antigen-activated T cells (2). Among the costimulatory receptors on T cells, CD28 has a pivotal role in the initiation and maintenance of T-cell responses. In various transplant models, inhibition of CD28:B7 interactions by CTLA4-Ig resulted in immunosuppression (3). However, treatment with anti-CD28 Abs was more effective than CTLA4-Ig in the prevention of graft-versus-host disease in mice (4). Therefore, selective targeting of CD28 may be a better approach to achieve transplantation tolerance than blocking B7 molecules, the ligands for both CD28 and CTLA4, as CTLA4 is inhibitory for T-cell activation. Here we tested the hypothesis that combined treatment with non-FcR-binding anti-CD3ε plus anti-CD28 Abs leads to transplantation tolerance by affecting independent and complementary pathways of T cell activation. The experiments were performed in the context of a strong allogeneic MHC stimulation by transplanting skin grafts from BALB/c (H2d) onto C57BL/6 (H2b) mice. Recipients were treated with control Ab, anti-CD28 alone, non-FcR-binding anti-CD3ε alone, or anti-CD3ε plus anti-CD28. As shown in Figure 1A, treatment with anti-CD3 significantly prolonged graft survival compared to control or anti-CD28 treatment (P <0.0001, P <0.0001), whereas anti-CD28 by itself was modestly effective (P =0.002). The combination of anti-CD3ε plus anti-CD28 Abs was significantly more effective than either Ab alone (P =0.002, and P <0.0001), but transplantation tolerance did not develop. We suspected that failure to achieve graft tolerance could result from non-tolerant T cells developing from the thymus after stopping treatment. These T cells could recognize alloantigens and reject the skin graft. To test this hypothesis, we utilized thymectomized C57BL/6 mice as recipients. Treatment with anti-CD3ε plus anti-CD28 Abs significantly prolonged graft survival compared to control Ab (Fig. 1B), but the magnitude of the effect was not significantly different in normal or thymectomized recipients (P =0.5). Figure 1: Prolongation of murine skin allograft survival. Normal (A) or thymectomized (B) C57BL/6 mice were transplanted with full-thickness skin grafts from BALB/c donors. Recipients were intraperitoneally injected with the reagents indicated once every other day for a total of eight doses. The dose of anti-CD3ε and anti-CD28 Abs were 80 and 100 μg/mouse, respectively. The control Ab used was normal hamster IgG.We conclude that anti-CD3 and anti-CD28 Abs have additive immunosuppressive effects, but their combination does not induce tolerance to skin transplants. The failure of inducing transplantation tolerance with this treatment is not caused by the emergence of non-tolerant T cells from the host thymus, but may result from incomplete depletion of alloreactive T cells, lack of inducing T-cell unresponsiveness, and/or lack of generating regulatory T cells. Xue-Zhong Yu1 Yoshio Nitta2,3 Sasha J. Bidwell1 Claudio Anasetti1,4